Real-World Effectiveness of Racotumomab as Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients.

Performance status by ECOG score was strongly associated with survival: patients with ECOG 0 had an MST of 22.5 months (95% CI, 12.1–32.9), ECOG 1 patients 13.3 months (95% CI, 10.4–16.3), and those with ECOG 2 had a markedly shorter MST of 3.3 months (95% CI, 2.8–3.8), with highly significant differences ( p = 0.0001) ( Figure 2 D).

also in 132,142 other papers

Conversely, patients with ECOG performance status 2 appeared to have better survival outcomes when treated with docetaxel, although this finding did not reach statistical significance. 4.

also in 111,027 other papers